GSK and Synta announce STA-4783 collaboration

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 11
Volume 16
Issue 11

GSK and Synta announce STA-4783 collaboration

LONDON, UK—GlaxoSmithKline and Synta Pharmaceuticals Corp have reached an agreement for the joint development and commercialization of STA-4783 (elesclomol), a first-in-class, small-molecule oxidative stress inducer that is entering phase III development for the treatment of metastatic melanoma (see page 19). The companies will share responsibility for development of STA-4783 in the United States, and GSK will have exclusive responsibility for development outside the US.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Experts on myeloma
Related Content